Q3 2022 13F Holders as of 30 Sep 2022
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
98,294,118
-
Total 13F shares
-
30,422,972
-
Share change
-
+4,359,277
-
Total reported value
-
$160,377,408
-
Put/Call ratio
-
61%
-
Price per share
-
$5.28
-
Number of holders
-
58
-
Value change
-
+$24,492,078
-
Number of buys
-
23
-
Number of sells
-
40
Institutional Holders of ARS Pharmaceuticals, Inc. - Common Stock (SPRY) as of Q3 2022
As of 30 Sep 2022,
ARS Pharmaceuticals, Inc. - Common Stock (SPRY) was held by
58 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
30,422,972 shares.
The largest 10 holders included
ORBIMED ADVISORS LLC, FMR LLC, K2 PRINCIPAL FUND, L.P., Rubric Capital Management LP, Nextech Invest AG, Nantahala Capital Management, LLC, VANGUARD GROUP INC, SECTORAL ASSET MANAGEMENT INC, Woodline Partners LP, and BlackRock Inc..
This page lists
58
institutional shareholders reporting positions in this security
for the Q3 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.